Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Chubb
McKesson
Farmers Insurance
Citi
Cipla

Generated: July 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 10,201,541

Try a free trialSee Plans and Pricing

« Back to Dashboard

Which drugs does patent 10,201,541 protect, and when does it expire?

Patent 10,201,541 protects VIEKIRA XR and is included in one NDA.

Summary for Patent: 10,201,541
Title:Compositions and methods for treating HCV
Abstract: This disclosure is directed to pharmaceutical compositions that comprise two or more therapeutic agents that, inter alia, are useful for inhibiting hepatitis C virus (HCV) and methods for inhibiting HCV by co-administering two or more anti-HCV therapeutic agents.
Inventor(s): Collins; Christine A. (Skokie, IL), Cohen; Daniel E. (Highland Park, IL), Koev; Gennadiy (Libertyville, IL), Krishnan; Preethi (Gurnee, IL), Pilot-Matias; Tami J. (Green Oaks, IL)
Assignee: ABBVIE INC. (North Chicago, IL)
Application Number:15/398,390
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 10,201,541
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 10,201,541

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Abbvie Inc VIEKIRA XR dasabuvir sodium; ombitasvir; paritaprevir; ritonavir TABLET, EXTENDED RELEASE;ORAL 208624-001 Jul 22, 2016 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
Citi
Cantor Fitzgerald
Accenture
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.